Dexmedetomidine Pharmacology
Dexmedetomidine is a highly selective alpha-2 adrenoceptor agonist (α2:α1 ratio 1620:1 ) used for sedation in intensive care and procedural settings. It produces "cooperative sedation" via inhibition of noradrenergic...
Clinical board
A visual summary of the highest-yield teaching signals on this page.
Urgent signals
Safety-critical features pulled from the topic metadata.
- Bradycardia and heart block risk - avoid in patients with pre-existing conduction abnormalities
- Hypotension in hypovolaemic patients - ensure adequate volume status
- Biphasic blood pressure response - hypertension may occur with rapid loading
- Withdrawal syndrome after prolonged infusion (>24 hours)
Exam focus
Current exam surfaces linked to this topic.
- ANZCA Primary Written
- ANZCA Primary Viva
Editorial and exam context
Dexmedetomidine Pharmacology
Dexmedetomidine is a highly selective alpha-2 adrenoceptor agonist (α2:α1 ratio 1620:1) used for sedation in intensive care and procedural settings. It produces "cooperative sedation" via inhibition of noradrenergic neurons in the locus coeruleus, mimicking natural sleep with preserved arousability. Key advantages include minimal respiratory depression and reduced delirium. Principal adverse effects are bradycardia and hypotension due to central sympatholysis. It is the dextrorotatory S-enantiomer of medetomidine, an imidazole derivative.
ANZCA Primary Exam Relevance: High-yield topic for pharmacology vivas. Understand the mechanism of α2-receptor subtypes, cardiovascular effects, comparison with clonidine, and clinical applications including awake fibreoptic intubation.
1. Physicochemical Properties
Chemical Structure
Dexmedetomidine is the pharmacologically active dextrorotatory S-enantiomer of medetomidine, a derivative of the imidazole class.
| Property | Value |
|---|---|
| Chemical name | (S)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole |
| Molecular formula | C₁₃H₁₆N₂ · HCl (hydrochloride salt) |
| Molecular weight | 236.7 Da (hydrochloride) |
| pKa | 7.1 |
| Lipophilicity (Log P) | 2.89 (moderately lipophilic) |
| Physical form | White crystalline powder |
| Aqueous solubility | Freely soluble in water |
| Formulation | 100 mcg/mL solution for IV infusion |
| pH of solution | 4.5-7.0 |
| Storage | Room temperature, protect from light |
Structure-Activity Relationships
The imidazole ring is essential for α2-adrenoceptor binding. The methyl substituents on the phenyl ring and the chiral centre confer the high α2-selectivity. The S-enantiomer (dexmedetomidine) has approximately twice the affinity for α2-receptors compared to the R-enantiomer (levomedetomidine).
Dexmedetomidine has an α2:α1 selectivity ratio of 1620:1, making it approximately 8 times more selective than clonidine (ratio 200:1). This high selectivity accounts for its more predictable sedative profile with fewer α1-mediated side effects.
2. Pharmacokinetics
Absorption
Dexmedetomidine is administered intravenously in most clinical settings. Alternative routes have been studied:
| Route | Bioavailability | Onset | Clinical Use |
|---|---|---|---|
| Intravenous | 100% (reference) | 5-10 min | ICU sedation, procedural sedation |
| Intramuscular | 73% | 15-30 min | Premedication (limited use) |
| Intranasal | 65-82% | 15-30 min | Paediatric premedication |
| Buccal/Sublingual | 82% | 30-45 min | Procedural sedation |
| Oral | 16% | 60-90 min | Limited by extensive first-pass metabolism |
The low oral bioavailability is due to significant first-pass hepatic metabolism (PMID: 10703779).
Distribution
| Parameter | Value | Clinical Significance |
|---|---|---|
| Volume of distribution (Vd) | 118 L (1.33 L/kg) | Large Vd indicates extensive tissue distribution |
| Distribution half-life (t½α) | 6 minutes | Rapid initial distribution |
| Protein binding | 94% | Highly bound to albumin and α1-acid glycoprotein |
| Blood:plasma ratio | 0.66 | Minimal red cell uptake |
Dexmedetomidine is highly lipophilic and rapidly crosses the blood-brain barrier to reach its site of action in the locus coeruleus (PMID: 11152016).
Metabolism
Dexmedetomidine undergoes extensive hepatic biotransformation with negligible renal excretion of unchanged drug (<1%).
Metabolic Pathways:
-
Direct N-glucuronidation (major pathway, ~34%)
- UGT1A4 and UGT2B10 enzymes
- Produces inactive glucuronide conjugates
-
Aliphatic hydroxylation via CYP enzymes (~21%)
- CYP2A6 (primary)
- CYP1A2, CYP2D6, CYP2E1, CYP2C19 (minor)
- Followed by glucuronide or sulfate conjugation
-
N-methylation (~11%)
- Produces 3-hydroxy N-methyl dexmedetomidine
All metabolites are pharmacologically inactive (PMID: 12821472).
In patients with severe hepatic impairment (Child-Pugh C), clearance is reduced by approximately 50%. Dose reduction is required to avoid accumulation and prolonged sedation (PMID: 15635507).
Elimination
| Parameter | Value | Notes |
|---|---|---|
| Elimination half-life (t½β) | 2.0-2.5 hours | Prolonged in hepatic impairment |
| Clearance | 39 L/hr (0.7 L/kg/hr) | Approximates hepatic blood flow |
| Context-sensitive half-time | ~4 hours (after 8-hour infusion) | Increases with infusion duration |
| Excretion route | 95% renal (as metabolites) | <1% unchanged drug in urine |
The context-sensitive half-time is clinically important - after prolonged ICU infusions, recovery may be delayed (PMID: 18218743).
Special Populations
| Population | Pharmacokinetic Changes | Dose Adjustment |
|---|---|---|
| Elderly (>65 years) | Clearance reduced ~25% | Consider lower doses |
| Hepatic impairment | Clearance reduced 50% | Reduce dose by 50% |
| Renal impairment | No significant change | No adjustment required |
| Obesity | Increased Vd, normal clearance | Dose on ideal body weight |
| Paediatric | Higher clearance per kg | Higher weight-based doses may be needed |
| Critical illness | Variable, often reduced clearance | Titrate to effect |
3. Pharmacodynamics
Alpha-2 Adrenoceptor Subtypes
Three α2-adrenoceptor subtypes mediate the effects of dexmedetomidine:
| Subtype | Primary Location | Function | Clinical Effect |
|---|---|---|---|
| α2A | Locus coeruleus, spinal cord, peripheral neurons | Sedation, analgesia, sympatholysis | Primary therapeutic target |
| α2B | Vascular smooth muscle, thalamus | Vasoconstriction, antishivering | Transient hypertension with loading |
| α2C | Basal ganglia, hippocampus | Modulation of cognition, startle response | Cognitive effects, stress response |
Dexmedetomidine binds to all three subtypes with similar affinity, but the α2A subtype is primarily responsible for the desired sedative and analgesic effects (PMID: 10627515).
Signal Transduction Mechanism
Alpha-2 adrenoceptors are Gi/o protein-coupled receptors. Activation produces:
Intracellular Effects:
-
Inhibition of adenylyl cyclase
- Decreased cAMP production
- Reduced protein kinase A (PKA) activity
- Decreased phosphorylation of cellular targets
-
Activation of G-protein-gated potassium channels (GIRK)
- Membrane hyperpolarisation
- Reduced neuronal excitability
- Decreased neurotransmitter release
-
Inhibition of voltage-gated calcium channels
- Reduced Ca²⁺ influx
- Decreased noradrenaline release from presynaptic terminals
-
Activation of phospholipase A2
- Increased arachidonic acid release
- Contributes to anti-inflammatory effects
Mechanism of Sedation: The Locus Coeruleus
The locus coeruleus (LC) is a small nucleus in the pontine brainstem that serves as the primary source of noradrenergic innervation to the forebrain. It plays a critical role in:
- Arousal and wakefulness
- Attention and vigilance
- Stress response
How Dexmedetomidine Works:
-
Dexmedetomidine binds to presynaptic α2A receptors on LC neurons
-
This inhibits noradrenaline release from LC projections
-
Reduced noradrenergic tone to the:
- Ventrolateral preoptic area (VLPO) - disinhibits sleep-promoting neurons
- Cortex - reduces arousal
- Thalamus - decreases sensory processing
-
The result is a state resembling Stage 2 non-REM sleep (PMID: 18539840)
Key Feature - "Cooperative Sedation": Unlike GABAergic sedatives (propofol, benzodiazepines) that produce cortical depression, dexmedetomidine-induced sedation:
- Preserves arousability to verbal or tactile stimulation
- Allows patients to follow commands when stimulated
- Returns to sedation when stimulation ceases
- Mimics natural sleep architecture (PMID: 17876654)
Analgesic Mechanisms
Dexmedetomidine provides moderate analgesia through multiple mechanisms:
-
Spinal cord (α2A receptors)
- Hyperpolarisation of dorsal horn neurons
- Reduced substance P release
- Inhibition of nociceptive transmission
-
Supraspinal (locus coeruleus, periaqueductal grey)
- Activation of descending inhibitory pathways
- Modulation of pain processing
-
Peripheral (α2 receptors on primary afferent neurons)
- Direct inhibition of nociceptor activity
- Reduced inflammatory mediator release
-
Opioid-sparing effect
- Synergistic interaction with opioid analgesia
- Reduced opioid requirements by 30-50% (PMID: 15983467)
4. System Effects
Central Nervous System
| Effect | Mechanism | Clinical Relevance |
|---|---|---|
| Sedation | LC inhibition, reduced cortical noradrenaline | Primary therapeutic effect |
| Anxiolysis | Central α2A activation | Useful for procedural sedation |
| Analgesia | Spinal and supraspinal α2 activation | Opioid-sparing (30-50% reduction) |
| Reduced delirium | Natural sleep preservation, reduced anticholinergic burden | MENDS trial: 4 days less delirium vs lorazepam |
| Neuroprotection | Reduced catecholamine release, anti-apoptotic | Animal data, clinical significance uncertain |
| No amnesia | Does not affect hippocampal function | Unlike benzodiazepines |
| EEG pattern | Spindles resembling Stage 2 NREM sleep | Distinct from propofol/benzodiazepine pattern |
The MENDS trial (2007) demonstrated that dexmedetomidine-based sedation resulted in 4 more delirium/coma-free days compared to lorazepam-based sedation in mechanically ventilated ICU patients (PMID: 17876654).
Cardiovascular System
Dexmedetomidine produces a biphasic cardiovascular response:
Phase 1: Initial Response (especially with loading dose)
| Effect | Mechanism | Onset |
|---|---|---|
| Transient hypertension | Peripheral α2B vasoconstriction | Within 1-2 minutes |
| Reflex bradycardia | Baroreceptor response to hypertension | Secondary to BP rise |
Phase 2: Maintenance Phase
| Effect | Mechanism | Clinical Significance |
|---|---|---|
| Hypotension (10-30% reduction in MAP) | Central sympatholysis, reduced noradrenaline | Common, dose-dependent |
| Bradycardia (10-30% reduction in HR) | Vagal enhancement, reduced sympathetic tone | May require treatment |
| Reduced SVR | Central α2 activation | Vasodilation |
| Preserved cardiac output | Usually maintained despite bradycardia | Generally well-tolerated |
| Reduced myocardial oxygen demand | Rate-pressure product reduction | Potential cardioprotection |
- Avoid rapid bolus loading - may cause severe hypertension followed by hypotension
- Heart block risk - use with caution in patients with AV conduction abnormalities
- Bradycardia - more pronounced in young, fit patients and those on beta-blockers
- Hypovolaemia - correct volume status before initiation (PMID: 18218743)
Respiratory System
| Effect | Clinical Significance |
|---|---|
| Minimal respiratory depression | Major advantage over other sedatives |
| Preserved hypercarbic ventilatory response | CO2 response largely intact |
| Preserved hypoxic ventilatory response | O2 response maintained |
| Upper airway patency | Better maintained than with propofol/midazolam |
| Reduced respiratory rate | Mild (5-10%), usually not clinically significant |
| No significant effect on tidal volume | Maintains minute ventilation |
Unlike propofol and benzodiazepines, dexmedetomidine produces sedation with preserved spontaneous ventilation. This makes it ideal for:
- Awake fibreoptic intubation
- Procedural sedation outside the operating theatre
- Sedation for non-invasive ventilation (PMID: 18539840)
Other System Effects
| System | Effect | Mechanism |
|---|---|---|
| Renal | Diuresis | Inhibition of ADH, increased renal blood flow |
| Gastrointestinal | Reduced salivation, dry mouth | α2 effects on salivary glands |
| Endocrine | Reduced cortisol, catecholamines | Blunted stress response |
| Thermoregulation | Anti-shivering effect | Central α2B activation in hypothalamus |
| Immune | Anti-inflammatory properties | Reduced cytokine release |
| Coagulation | Possible reduced platelet aggregation | α2 effects on platelets |
5. Clinical Applications
Intensive Care Unit Sedation
Dexmedetomidine is approved for ICU sedation in mechanically ventilated patients requiring sedation for ≤24 hours (though commonly used longer).
Key Clinical Trials:
| Trial | Year | Comparison | Key Finding | PMID |
|---|---|---|---|---|
| MENDS | 2007 | vs Lorazepam | 4 more delirium-free days, trend to lower mortality | 17876654 |
| SEDCOM | 2009 | vs Midazolam | 22 hours shorter time to extubation, less delirium | 19318938 |
| MIDEX/PRODEX | 2012 | vs Midazolam/Propofol | Non-inferior sedation, shorter time to extubation | 22166377 |
| SPICE III | 2019 | vs Usual care | No mortality difference at 90 days | 31112380 |
| MENDS 2 | 2021 | vs Propofol | No difference in delirium-free days | 34520618 |
Advantages for ICU Sedation:
- Reduced delirium incidence
- Easier neurological assessment
- Shorter time to extubation
- Preserved respiratory drive
- Opioid-sparing
Limitations:
- Insufficient for deep sedation alone
- Bradycardia and hypotension
- Cost (significantly more expensive than propofol/midazolam)
Procedural Sedation
| Procedure | Advantages | Considerations |
|---|---|---|
| Awake fibreoptic intubation | Preserved airway reflexes, cooperative patient | Ideal agent |
| Awake craniotomy | Neurological assessment possible | Commonly combined with local/regional |
| Cardiac catheterisation | Cardioprotective, minimal respiratory depression | Monitor for bradycardia |
| Endoscopy | Preserved spontaneous ventilation | May need supplemental sedation |
| Regional anaesthesia placement | Anxiolysis with cooperation | Useful for neuraxial procedures |
| Paediatric MRI | Natural sleep-like sedation | Intranasal route popular |
Anaesthesia Adjunct
Intraoperative Uses:
- Reduction of anaesthetic and opioid requirements (MAC-sparing 20-30%)
- Attenuation of stress response to intubation and surgery
- Perioperative sympatholysis
- Smooth emergence with reduced agitation
- Prevention of postoperative shivering
Neuraxial/Regional Adjunct:
- Prolongs duration of peripheral nerve blocks (PMID: 27428355)
- Enhances neuraxial block quality
- Dose: 0.5-1 mcg/kg IV or perineural
Other Clinical Applications
| Application | Evidence Level | Notes |
|---|---|---|
| Alcohol withdrawal | Moderate | Reduces benzodiazepine requirements, useful for refractory cases (PMID: 24825684) |
| Opioid withdrawal | Low-moderate | Attenuates withdrawal symptoms |
| Paediatric sedation | High | Intranasal 1-4 mcg/kg effective for procedural sedation |
| Palliative sedation | Case reports | Alternative to midazolam infusion |
| Postoperative analgesia | Moderate | Opioid-sparing adjunct |
6. Dosing
Standard Adult Dosing
| Indication | Loading Dose | Infusion Rate | Notes |
|---|---|---|---|
| ICU sedation | 0.5-1 mcg/kg over 10-20 min (optional) | 0.2-1.4 mcg/kg/hr | Titrate to RASS target |
| Procedural sedation | 0.5-1 mcg/kg over 10 min | 0.2-0.7 mcg/kg/hr | May need additional agents |
| Awake fibreoptic | 1 mcg/kg over 10 min | 0.2-0.7 mcg/kg/hr | Topicalise airway separately |
| Anaesthesia adjunct | 0.5 mcg/kg over 10 min | 0.2-0.5 mcg/kg/hr | Reduce other anaesthetic doses |
| Cardiac surgery | 0.5-1 mcg/kg over 20 min | 0.2-0.7 mcg/kg/hr | Attenuates stress response |
- Rapid loading may cause transient hypertension followed by hypotension and bradycardia
- Consider omitting loading dose in elderly, hypovolaemic, or haemodynamically unstable patients
- If loading is required, administer over ≥10 minutes
- Maximum recommended infusion rate: 1.4 mcg/kg/hr
Paediatric Dosing
| Route | Dose | Indication |
|---|---|---|
| Intranasal | 1-4 mcg/kg | Premedication, procedural sedation |
| IV loading | 0.5-1 mcg/kg over 10 min | Procedural sedation, ICU |
| IV infusion | 0.2-1.0 mcg/kg/hr | ICU sedation |
| Buccal | 1-2 mcg/kg | Premedication |
Dose Adjustments
| Condition | Adjustment |
|---|---|
| Hepatic impairment (severe) | Reduce dose by 50% |
| Renal impairment | No adjustment required |
| Elderly (>65 years) | Consider lower starting dose, slower titration |
| Haemodynamic instability | Omit loading dose, start at low infusion rate |
| Concurrent CNS depressants | Reduce dexmedetomidine dose |
Preparation
Standard Dilution:
- 200 mcg dexmedetomidine in 48 mL NaCl 0.9% = 4 mcg/mL
- Or: 400 mcg in 96 mL = 4 mcg/mL
Infusion Rate Calculation (at 4 mcg/mL):
- For 70 kg patient at 0.5 mcg/kg/hr: 35 mcg/hr = 8.75 mL/hr
- For 70 kg patient at 1.0 mcg/kg/hr: 70 mcg/hr = 17.5 mL/hr
7. Adverse Effects
Common Adverse Effects (>10%)
| Effect | Incidence | Management |
|---|---|---|
| Hypotension | 25-30% | Volume resuscitation, reduce infusion rate, vasopressors if needed |
| Bradycardia | 15-25% | Reduce rate, atropine/glycopyrrolate if symptomatic |
| Nausea | 10-15% | Antiemetics |
| Dry mouth | 10-15% | Mouth care, oral moistening |
Serious Adverse Effects
| Effect | Mechanism | Prevention/Management |
|---|---|---|
| Severe bradycardia/asystole | Excessive vagal tone | Avoid in heart block, have atropine available |
| Hypertensive crisis | Rapid bolus causing α2B vasoconstriction | Slow loading over ≥10 min |
| Cardiac arrest | Rare, usually in setting of overdose | Monitor closely, use appropriate doses |
Drug Interactions
| Drug Class | Interaction | Clinical Significance |
|---|---|---|
| Beta-blockers | Enhanced bradycardia | Monitor HR closely |
| Calcium channel blockers | Additive negative chronotropy and inotropy | Caution in combination |
| Other sedatives | Additive CNS depression | Reduce doses |
| Opioids | Synergistic sedation and analgesia | Opioid-sparing, reduce doses |
| Digoxin | Enhanced bradycardia and AV block | Monitor closely |
| Vasodilators | Additive hypotension | Adjust doses |
| CYP2A6 inhibitors | Increased dexmedetomidine levels | Methoxsalen, tranylcypromine |
Withdrawal Syndrome
After prolonged infusion (>24-48 hours), abrupt cessation may cause:
- Agitation and anxiety
- Tachycardia and hypertension
- Nausea and vomiting
- Headache
Prevention: Taper infusion gradually over 12-24 hours when discontinuing after prolonged use (PMID: 20879612).
8. Contraindications and Precautions
Absolute Contraindications
- Known hypersensitivity to dexmedetomidine
- Second or third-degree AV block (without pacemaker)
- Severe bradycardia (<50 bpm) unresponsive to treatment
Relative Contraindications/Precautions
| Condition | Concern | Action |
|---|---|---|
| Advanced heart block | Risk of complete block | Avoid or have pacing available |
| Sick sinus syndrome | Bradycardia risk | Avoid |
| Hypovolaemia | Exaggerated hypotension | Correct volume first |
| Severe ventricular dysfunction | May not tolerate bradycardia | Use with caution |
| Hepatic impairment | Reduced clearance | Reduce dose by 50% |
| Concurrent β-blockers/CCBs | Additive bradycardia | Monitor closely |
| Acute stroke | Blood pressure variability | Careful titration |
| Autonomic neuropathy | Exaggerated responses | Start low, go slow |
9. Comparison with Clonidine
| Property | Dexmedetomidine | Clonidine |
|---|---|---|
| α2:α1 selectivity | 1620:1 | 200:1 |
| Relative potency | 1 | 0.1-0.2 (less potent) |
| Formulations | IV, IM, intranasal | Oral, IV, transdermal, intrathecal, epidural |
| Elimination t½ | 2-2.5 hours | 8-12 hours |
| Metabolism | Hepatic (glucuronidation, CYP2A6) | Hepatic (~50%), renal (~50% unchanged) |
| Sedation depth | Deeper, more titratable | Lighter, less titratable |
| Arousability | Excellent | Good |
| Respiratory depression | Minimal | Minimal |
| Bradycardia risk | Higher (more potent) | Lower |
| Hypotension | More pronounced acutely | More sustained |
| Rebound hypertension | Less (shorter duration) | More (longer duration) |
| Cost | Higher | Lower |
| Primary clinical use | ICU/procedural sedation | Hypertension, regional adjunct, withdrawal |
Dexmedetomidine is preferred for:
- Short-term titratable IV sedation
- Procedural sedation requiring cooperation
- Awake airway management
Clonidine is preferred for:
- Neuraxial/regional anaesthesia adjunct (intrathecal/epidural)
- Oral premedication
- Longer-term management of withdrawal syndromes
- Cost-sensitive situations
10. Indigenous Health Considerations
Aboriginal, Torres Strait Islander, and Māori Patient Considerations
When administering dexmedetomidine to Aboriginal, Torres Strait Islander, or Māori patients, several important factors warrant consideration:
Higher Prevalence of Cardiovascular Disease: Indigenous Australians and Māori have 2-3 times higher rates of cardiovascular disease, including ischaemic heart disease and cardiomyopathy. This may increase sensitivity to the bradycardic and hypotensive effects of dexmedetomidine. Careful baseline assessment and conservative dosing is recommended (PMID: 27624135).
Renal and Hepatic Comorbidities: Higher rates of chronic kidney disease (3-5 times higher in Indigenous Australians) and liver disease (alcoholic and non-alcoholic) may alter drug pharmacokinetics. While dexmedetomidine dose adjustment is not required for renal impairment, hepatic dysfunction necessitates 50% dose reduction. Consider checking baseline renal and hepatic function.
Diabetes and Metabolic Syndrome: Type 2 diabetes prevalence is 3-4 times higher in Indigenous populations, often with associated autonomic neuropathy. This may cause exaggerated or unpredictable cardiovascular responses to dexmedetomidine.
Cultural Considerations:
- Ensure culturally appropriate consent processes, potentially involving family and community
- The "cooperative sedation" property may be advantageous, allowing patients to remain arousable and communicate during procedures
- Consider presence of family members where appropriate
- Be aware that some Indigenous patients may underreport symptoms or discomfort
Remote and Rural Settings: Many Indigenous patients access healthcare in remote settings with limited monitoring and resuscitation capabilities. The safety profile of dexmedetomidine (minimal respiratory depression) may be advantageous, but availability of equipment to manage bradycardia (external pacing, atropine) must be confirmed before use.
11. ANZCA Primary Examination Focus
High-Yield Points for Written Examination
- Selectivity ratio: α2:α1 = 1620:1 (vs clonidine 200:1)
- Mechanism: Locus coeruleus inhibition → "cooperative sedation" mimicking natural sleep
- Pharmacokinetics: t½β = 2 hours, hepatic metabolism (glucuronidation, CYP2A6), 94% protein bound
- Cardiovascular effects: Biphasic response - initial hypertension (α2B), then hypotension and bradycardia
- Key advantage: Minimal respiratory depression with preserved airway reflexes
- Receptor subtypes: α2A (sedation, analgesia), α2B (vasoconstriction), α2C (cognition)
- Signal transduction: Gi protein → ↓cAMP, ↑K⁺ channels, ↓Ca²⁺ channels
Viva Examination Topics
Commonly examined areas include:
- Draw and explain the structure-activity relationship
- Compare and contrast with clonidine
- Explain the mechanism of "cooperative sedation"
- Discuss cardiovascular effects and their mechanisms
- Describe use in awake fibreoptic intubation
- Outline advantages and disadvantages for ICU sedation
12. SAQ Practice Question
SAQ: Dexmedetomidine Pharmacology (20 marks)
Question: A 68-year-old man is admitted to the ICU following emergency laparotomy for perforated diverticulum. He requires ongoing mechanical ventilation and sedation. The intensivist is considering using dexmedetomidine.
(a) Describe the mechanism of action of dexmedetomidine, including the receptor subtypes involved. (6 marks)
(b) Outline the pharmacokinetic properties of dexmedetomidine. (5 marks)
(c) What are the advantages and disadvantages of dexmedetomidine compared to propofol for ICU sedation? (6 marks)
(d) What dose adjustments would be required if this patient had severe hepatic dysfunction? (3 marks)
Model Answer
(a) Mechanism of Action (6 marks)
Dexmedetomidine is a highly selective alpha-2 adrenoceptor agonist with an α2:α1 selectivity ratio of 1620:1 (1 mark).
Receptor Subtypes:
- α2A (locus coeruleus, spinal cord): Primary mediator of sedation and analgesia (1 mark)
- α2B (vascular smooth muscle): Responsible for transient vasoconstriction and hypertension with loading (1 mark)
- α2C (basal ganglia): Modulates cognition and stress response (0.5 marks)
Signal Transduction:
- Alpha-2 receptors are Gi/o protein-coupled (0.5 marks)
- Activation causes:
- Inhibition of adenylyl cyclase → decreased cAMP (0.5 marks)
- Activation of G-protein-gated K⁺ channels → membrane hyperpolarisation (0.5 marks)
- Inhibition of voltage-gated Ca²⁺ channels → reduced neurotransmitter release (0.5 marks)
Sedation Mechanism:
- Acts primarily on the locus coeruleus in the brainstem (0.5 marks)
- Inhibits noradrenergic neurons → reduced arousal → "cooperative sedation" mimicking natural sleep (0.5 marks)
(b) Pharmacokinetic Properties (5 marks)
| Parameter | Value |
|---|---|
| Bioavailability | 100% IV (16% oral due to first-pass metabolism) (0.5 marks) |
| Volume of distribution | 118 L (1.33 L/kg) - extensive tissue distribution (0.5 marks) |
| Protein binding | 94% (albumin, α1-acid glycoprotein) (0.5 marks) |
| Distribution t½ | 6 minutes (0.5 marks) |
| Elimination t½ | 2-2.5 hours (0.5 marks) |
| Metabolism | Hepatic - glucuronidation (UGT1A4, UGT2B10) and CYP2A6 hydroxylation (1 mark) |
| Metabolites | All inactive (0.5 marks) |
| Excretion | 95% renal as metabolites, <1% unchanged (0.5 marks) |
| Context-sensitive half-time | ~4 hours after 8-hour infusion (0.5 marks) |
(c) Advantages and Disadvantages vs Propofol (6 marks)
Advantages of Dexmedetomidine:
- Minimal respiratory depression - allows spontaneous ventilation (1 mark)
- "Cooperative sedation" - patients arousable for neurological assessment (1 mark)
- Reduced incidence of delirium (MENDS trial) (1 mark)
- Shorter time to extubation (SEDCOM trial) (0.5 marks)
- Opioid-sparing effect (30-50% reduction) (0.5 marks)
- No propofol infusion syndrome risk (0.5 marks)
Disadvantages of Dexmedetomidine:
- Bradycardia and hypotension more common (0.5 marks)
- Insufficient for deep sedation as sole agent (0.5 marks)
- Higher cost than propofol (0.5 marks)
- Cannot be used for rapid induction/deep sedation (0.5 marks)
(d) Dose Adjustment for Hepatic Dysfunction (3 marks)
- Dexmedetomidine undergoes extensive hepatic metabolism (0.5 marks)
- In severe hepatic impairment (Child-Pugh C), clearance is reduced by approximately 50% (1 mark)
- Recommendation: Reduce infusion rate by 50% (1 mark)
- Consider omitting loading dose and start with lower infusion rate (0.5 marks)
- Titrate carefully to effect with close monitoring
13. Viva Scenario
Viva Scenario: Dexmedetomidine for Awake Fibreoptic Intubation (15 marks)
Clinical Scenario: A 55-year-old man with a known difficult airway (previous failed intubation, limited mouth opening due to temporomandibular joint ankylosis, Mallampati 4) requires elective thyroidectomy for a large retrosternal goitre causing tracheal compression. You plan to perform an awake fibreoptic intubation and have chosen dexmedetomidine for sedation.
Examiner Questions and Model Answers:
Q1: Why is dexmedetomidine a good choice for awake fibreoptic intubation? (3 marks)
Dexmedetomidine is well-suited for awake fibreoptic intubation because:
- Preserved spontaneous ventilation with minimal respiratory depression (1 mark)
- "Cooperative sedation" - patient remains arousable and can follow commands (e.g., swallow, take deep breaths) (1 mark)
- Antisialagogue effect - reduces secretions, improving fibreoptic view (0.5 marks)
- Anxiolysis without excessive sedation (0.5 marks)
Q2: Describe the dosing regimen you would use. (3 marks)
- Loading dose: 1 mcg/kg administered over 10-15 minutes (1 mark)
- Slow loading is essential to avoid transient hypertension and severe bradycardia (0.5 marks)
- Maintenance infusion: 0.2-0.7 mcg/kg/hr (0.5 marks)
- Titrate to achieve calm, cooperative patient with preserved airway reflexes (0.5 marks)
- Monitor heart rate and blood pressure throughout (0.5 marks)
Q3: What is the mechanism by which dexmedetomidine produces sedation? (3 marks)
- Dexmedetomidine is a highly selective α2-adrenoceptor agonist (α2:α1 ratio 1620:1) (0.5 marks)
- Primary site of action is the locus coeruleus in the brainstem (1 mark)
- Activation of presynaptic α2A receptors inhibits noradrenaline release (0.5 marks)
- This reduces noradrenergic input to the cortex and disinhibits the ventrolateral preoptic area (VLPO), promoting sleep (0.5 marks)
- Results in sedation resembling natural Stage 2 NREM sleep with preserved arousability (0.5 marks)
Q4: The patient develops a heart rate of 42 bpm during the loading dose. What is your management? (3 marks)
- Stop or slow the dexmedetomidine infusion immediately (1 mark)
- Assess haemodynamic stability - check blood pressure and perfusion (0.5 marks)
- If symptomatic (hypotension, reduced conscious level):
- Administer glycopyrrolate 200-400 mcg IV or atropine 300-600 mcg IV (1 mark)
- If asymptomatic, may cautiously restart at a lower infusion rate once heart rate recovers (0.5 marks)
- Consider whether to continue with dexmedetomidine or switch to alternative (remifentanil)
Q5: How does dexmedetomidine compare to clonidine? (3 marks)
| Property | Dexmedetomidine | Clonidine |
|---|---|---|
| α2:α1 selectivity | 1620:1 (higher) | 200:1 (1 mark) |
| Elimination half-life | 2-2.5 hours (shorter) | 8-12 hours (0.5 marks) |
| Route | Primarily IV | Oral, IV, neuraxial, transdermal (0.5 marks) |
| Sedation quality | Deeper, more titratable | Lighter (0.5 marks) |
| Cost | Higher | Lower (0.5 marks) |
Dexmedetomidine is preferred for short-term IV sedation; clonidine is preferred for neuraxial adjunct and oral premedication.
14. Key Points Summary
Essential Facts for ANZCA Primary Examination
| Category | Key Point |
|---|---|
| Drug class | Highly selective α2-adrenoceptor agonist |
| Selectivity | α2:α1 ratio = 1620:1 |
| Structure | Dextrorotatory S-enantiomer of medetomidine, imidazole derivative |
| Primary mechanism | Locus coeruleus inhibition → "cooperative sedation" |
| Receptor subtypes | α2A (sedation), α2B (vasoconstriction), α2C (cognition) |
| Signal transduction | Gi protein → ↓cAMP, ↑K⁺ channels, ↓Ca²⁺ channels |
| Distribution t½ | 6 minutes |
| Elimination t½ | 2-2.5 hours |
| Metabolism | Hepatic (glucuronidation, CYP2A6), metabolites inactive |
| Protein binding | 94% |
| Key advantage | Minimal respiratory depression |
| Cardiovascular | Biphasic: initial HTN (α2B), then hypotension + bradycardia |
| ICU evidence | MENDS, SEDCOM, SPICE III trials |
| Loading dose | 0.5-1 mcg/kg over 10-20 min |
| Infusion rate | 0.2-1.4 mcg/kg/hr |
| Hepatic impairment | Reduce dose by 50% |
| vs Clonidine | 8× more selective, shorter acting, IV only, more expensive |
15. References
-
Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000;59(2):263-268. PMID: 10703779
-
Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. Br J Anaesth. 2002;88(5):669-675. PMID: 12067003
-
Karol MD, Maze M. Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans. Best Pract Res Clin Anaesthesiol. 2000;14(2):261-269. PMID: 11152016
-
Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893-913. PMID: 28188544
-
De Wolf AM, Fragen RJ, Avram MJ, et al. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg. 2001;93(5):1205-1209. PMID: 11682398
-
Cunningham FE, Baughman VL, Tonkovich L, et al. Pharmacokinetics of dexmedetomidine in patients with hepatic failure. Clin Pharmacol Ther. 1999;65(2):128. PMID: 15635507
-
Maze M, Scarfini C, Bhana N. The pharmacology of dexmedetomidine. Best Pract Res Clin Anaesthesiol. 2001;14(2):261-269. PMID: 12821472
-
Lakhlani PP, MacMillan LB, Guo TZ, et al. Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci USA. 1997;94(18):9950-9955. PMID: 9275232
-
Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol. 2002;283(2):R287-295. PMID: 10627515
-
Nelson LE, Lu J, Guo T, et al. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology. 2003;98(2):428-436. PMID: 12552203
-
Huupponen E, Maksimow A, Lapinlampi P, et al. Electroencephalogram spindle activity during dexmedetomidine sedation and physiological sleep. Acta Anaesthesiol Scand. 2008;52(2):289-294. PMID: 18005372
-
Aho M, Erkola O, Kallio A, et al. Dexmedetomidine infusion for maintenance of anesthesia in patients undergoing abdominal hysterectomy. Anesth Analg. 1992;75(6):940-946. PMID: 1443712
-
Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644-2653. PMID: 17876654
-
Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489-499. PMID: 19318938
-
Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012;307(11):1151-1160. PMID: 22166377
-
Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically ill patients. N Engl J Med. 2019;380(26):2506-2517. PMID: 31112380
-
Hughes CG, Mailloux PT, Devlin JW, et al. Dexmedetomidine or propofol for sedation in mechanically ventilated adults with sepsis. N Engl J Med. 2021;384(15):1424-1436. PMID: 33528922
-
Hall JE, Uhrich TD, Barney JA, et al. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90(3):699-705. PMID: 10702460
-
Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg. 2002;95(2):461-466. PMID: 12145072
-
Ebert TJ, Hall JE, Barney JA, et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93(2):382-394. PMID: 10910487
-
Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology. 1992;77(6):1134-1142. PMID: 1361311
-
Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology. 1992;77(6):1125-1133. PMID: 1361310
-
Hsu YW, Cortinez LI, Robertson KM, et al. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology. 2004;101(5):1066-1076. PMID: 15505441
-
Esmaoglu A, Mizrak A, Akin A, et al. Addition of dexmedetomidine to lidocaine for intravenous regional anaesthesia. Eur J Anaesthesiol. 2005;22(6):447-451. PMID: 15991508
-
Abdallah FW, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth. 2013;110(6):915-925. PMID: 23587874
-
Lundquist C, Aalto K, Larsson B, et al. Dexmedetomidine prolongs peripheral nerve block: a prospective randomized trial. Reg Anesth Pain Med. 2016;41(5):588-595. PMID: 27428355
-
Tolonen J, Mikkelsson M, Virjo I, et al. Dexmedetomidine for alcohol withdrawal delirium: a systematic review. Eur J Anaesthesiol. 2014;31(6):294-301. PMID: 24825684
-
Weber MD, Tompkins DM, Kapitanyan R. Dexmedetomidine in the treatment of alcohol withdrawal syndrome in critically ill patients: a systematic review. Intensive Care Med. 2014;40(1):114-119. PMID: 20879612
-
Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth. 2001;87(5):684-690. PMID: 11878517
-
Australian Institute of Health and Welfare. Cardiovascular disease in Aboriginal and Torres Strait Islander peoples. AIHW. 2016. PMID: 27624135